JP5426554B2 - ドネペジル塩、その多形体、その製造方法、応用方法および組成物 - Google Patents

ドネペジル塩、その多形体、その製造方法、応用方法および組成物 Download PDF

Info

Publication number
JP5426554B2
JP5426554B2 JP2010526129A JP2010526129A JP5426554B2 JP 5426554 B2 JP5426554 B2 JP 5426554B2 JP 2010526129 A JP2010526129 A JP 2010526129A JP 2010526129 A JP2010526129 A JP 2010526129A JP 5426554 B2 JP5426554 B2 JP 5426554B2
Authority
JP
Japan
Prior art keywords
donepezil
acid
solution
compound represented
chemical formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010526129A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540470A (ja
JP2010540470A5 (enExample
Inventor
和▲勝▼ ▲張▼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tianjin Hemay Bio Tech CoLtd
Original Assignee
Tianjin Hemay Bio Tech CoLtd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tianjin Hemay Bio Tech CoLtd filed Critical Tianjin Hemay Bio Tech CoLtd
Publication of JP2010540470A publication Critical patent/JP2010540470A/ja
Publication of JP2010540470A5 publication Critical patent/JP2010540470A5/ja
Application granted granted Critical
Publication of JP5426554B2 publication Critical patent/JP5426554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C07C65/10—Salicylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010526129A 2007-09-28 2008-09-24 ドネペジル塩、その多形体、その製造方法、応用方法および組成物 Expired - Fee Related JP5426554B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN200710061212.0 2007-09-28
CN200710061212 2007-09-28
CN200810052067.4 2008-01-15
CN200810052067 2008-01-15
CN200810211731.5 2008-09-24
PCT/CN2008/001646 WO2009049479A1 (en) 2007-09-28 2008-09-24 Polymorphs of donepezil salts, preparation methods and uses thereof
CN2008102117315A CN101397270B (zh) 2007-09-28 2008-09-24 多奈哌齐盐的多晶型物及其制备和应用

Publications (3)

Publication Number Publication Date
JP2010540470A JP2010540470A (ja) 2010-12-24
JP2010540470A5 JP2010540470A5 (enExample) 2013-12-05
JP5426554B2 true JP5426554B2 (ja) 2014-02-26

Family

ID=40566980

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010526129A Expired - Fee Related JP5426554B2 (ja) 2007-09-28 2008-09-24 ドネペジル塩、その多形体、その製造方法、応用方法および組成物

Country Status (7)

Country Link
US (2) US8501779B2 (enExample)
EP (1) EP2204364B1 (enExample)
JP (1) JP5426554B2 (enExample)
CN (2) CN102603612A (enExample)
DK (1) DK2204364T3 (enExample)
ES (1) ES2415166T3 (enExample)
WO (1) WO2009049479A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113793A1 (en) * 2006-03-20 2010-05-06 Ind-Swift Laboratories Limited Process for the Preparation of Highly Pure Donepezil
JP5563841B2 (ja) * 2010-02-05 2014-07-30 沢井製薬株式会社 薬物の不快な味をマスキングした経口医薬組成物
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
CN104958254A (zh) * 2015-06-27 2015-10-07 万特制药(海南)有限公司 一种盐酸多奈哌齐口服溶液及其制备方法
KR102318249B1 (ko) * 2018-11-26 2021-10-27 에바바이오 주식회사 도네페질 이온성 액체 및 이의 용도
WO2020111719A2 (ko) * 2018-11-26 2020-06-04 연세대학교 산학협력단 도네페질 공융혼합물 및 이의 용도
US20230054895A1 (en) * 2020-01-10 2023-02-23 President And Fellows Of Harvard College Methods for inducing biostasis in a cell, tissue or organ

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
NZ333197A (en) * 1996-06-07 2001-03-30 Eisai Co Ltd Polymorphs of donepezil hydrochloride
JPH1053576A (ja) * 1996-06-07 1998-02-24 Eisai Co Ltd 塩酸ドネペジルの多形結晶およびその製造法
US7439365B2 (en) 2003-11-17 2008-10-21 Usv, Ltd. Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil)
US20050288330A1 (en) * 2004-06-29 2005-12-29 Avinash Naidu Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
HUP0401850A3 (en) 2004-09-15 2008-03-28 Egis Gyogyszergyar Nyilvanosan Donepezil salts for producing pharmaceutical composition
DE102004046497A1 (de) * 2004-09-23 2006-04-06 Helm Ag Donepezil-Salze
CA2581926A1 (en) * 2004-09-29 2006-04-06 Chemagis Ltd. Use of purified donepezil maleate for preparing pharmaceutically pure amorphous donepezil hydrochloride
CN1759836A (zh) * 2004-10-12 2006-04-19 天津和美生物技术有限公司 多奈哌齐及其衍生物的舌下含片
WO2007010910A1 (en) * 2005-07-15 2007-01-25 Eisai R & D Management Co., Ltd. 1-benzyl-4-[(5, 6-dimethoxy-1-indanon)-2-yl]-methyl piperidine p-toluenesulfonate or crystal thereof
HU227474B1 (en) * 2005-12-20 2011-07-28 Richter Gedeon Nyrt Process for industrial scale production of high purity donepezil hydrochloride polymorph i.

Also Published As

Publication number Publication date
JP2010540470A (ja) 2010-12-24
WO2009049479A1 (en) 2009-04-23
DK2204364T3 (da) 2013-06-03
HK1146047A1 (en) 2011-05-13
EP2204364B1 (en) 2013-03-20
US20130296283A1 (en) 2013-11-07
US20100311793A1 (en) 2010-12-09
CN101397270B (zh) 2012-03-28
CN101397270A (zh) 2009-04-01
EP2204364A1 (en) 2010-07-07
ES2415166T3 (es) 2013-07-24
CN102603612A (zh) 2012-07-25
US8501779B2 (en) 2013-08-06
EP2204364A4 (en) 2011-08-10

Similar Documents

Publication Publication Date Title
JP5426554B2 (ja) ドネペジル塩、その多形体、その製造方法、応用方法および組成物
JP2005015486A (ja) 塩酸ドネペジルの多形結晶およびその製造法
AU2016358448B2 (en) Salts of tetracyclines
WO2010130139A1 (zh) 芳基(乙)丙酸抗坏血酸酯，其制备方法及含有它们的药物
EP3480200B1 (en) Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same
TW200536845A (en) Crystalline polymorph of bazedoxifene acetate
JP2010540470A5 (enExample)
WO2023221825A1 (zh) 一种倍半萜衍生物、其药物组合物及其制备方法和用途
KR100339115B1 (ko) 결정성3-(4-헥실옥시-1,2,5-티아디아졸-3-일)-1,2,5,6-테트라하이드로-1-메틸피리딘(+)l-하이드로겐타르트레이트,이의제조방법및이를포함하는약제학적조성물
JP5562337B2 (ja) ドネペジルの多形結晶及びその製造方法
HK1146047B (en) Polymorphs of donepezil salts, preparation methods and uses thereof
CN118812406A (zh) 一种酰胺基烷基间苯二酚衍生物及其作为抗氧化剂的用途
TWI267511B (en) Process for preparing 10,11-methanobenzosuberane derivatives
JP7359769B2 (ja) ピラノース置換複素環式化合物の塩、その調製方法および用途
JP3864991B2 (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
JP2010077155A (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
KR20250081156A (ko) L-세린 염산염의 제조 방법 및 이의 용도
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
JPH0466568A (ja) 中枢性抗酸化剤化合物
JP2006160766A (ja) （±）２−（ジメチルアミノ）−１−｛〔Ｏ−（ｍ−メトキシフェネチル）フェノキシ〕メチル｝エチル水素サクシナート塩酸塩の結晶
TW200526659A (en) New compounds
JP2008504369A (ja) １，２４（ｓ）−ジヒドロキシビタミンｄ２の結晶形態
JPH05208976A (ja) ピペリジン誘導体およびそれを含有する降圧剤
TW201720832A (zh) 喹諾酮類似物及其鹽的結晶形式

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20131017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131128

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees